AI-Powered Drug DEVELOPMENT
Faster Paths
to Safer Drugs
Extend the life and impact of your drugs with AI-driven coformers that make formulations safer, more effective, and faster to market.
the problem
Poor solubility leads to wasted pipelines, higher risks,
and fewer therapeutic options.
Nearly half of commercialized drugs suffer from poor solubility, resulting in low bioavailability and detrimental side effects for patients.
Over a million serious adverse events are reported each year with many that can be improved through better formulations.
Poor solubility plays a major role in late stage drug development failures leading to over $20B in annual waste.
the SOLUTION
Coformer AI accelerates the process end-to-end, helping you formulate and validate in small-scale human trials within 12 months.
AI-powered screening pairs APIs with coformers using proprietary molecular mechanism models to overcome solubility and bioavailability barriers.
Robotics quickly validate solubility gains, with partners advancing the best candidates into small-scale human trials.
Continuous feedback loops refine formulations for maximum bioavailability, safety,
and dosage efficiency.
Get proof of viabaility within a year and a clear path to FDA approval
in 3 years — reducing cost, risk, and time to impact.
benefits
Accelerate development timelines, lower the costs of reformulation, and give your therapies a decisive edge over competitors.
Extend the value of blockbuster drugs with formulations that keep revenue flowing.
Solve solubility bottlenecks with rigorous AI workflows — not guesswork.
Deliver safer, more effective formulations up to 10x faster than traditional methods.
The Differentiator
For teams facing bottlenecks in drug development, Coformer AI delivers targeted coformer solutions that unlock solubility and keep pipelines moving.
For companies seeking greater value, Coformer AI develops and licenses finished formulations — ready for clinical advancement and market success.
HOW IT WORKS
Identify APIs where poor solubility threatens market viability or patient outcomes.
Multi-agent AI pinpoints the right coformer pairings to overcome barriers.
Robotics-driven in vitro testing delivers quick confirmation, with partners advancing to small-scale human trials in as little as 12 months.
Optimized formulations move forward to regulatory approval and commercial readiness — typically within three years, not decades.
Whether extending lifecycles or advancing new therapies,
Coformer AI makes it possible.
Extend the Life of Existing Drugs
Identify APIs where poor solubility threatens market viability or patient outcomes.
Accelerate New Therapies
Overcome solubility challenges early, reducing years of costly trial and error while boosting odds of clinical and regulatory success.
PARTNER
“Coformer AI delivered measurable solubility improvements across multiple APIs in just weeks — a pace I’ve never seen before in this industry. This technology has the potential to transform how we approach drug development.”
CEO, Carnegie Pharmaceuticals, LLC
Copyright © 2025. All rights reserved.